Form 4: BioCardia CEO Buys Shares Under 10b5-1 Plan

BioCardia's President and CEO, Peter Altman, acquired 400 shares of common stock through a pre-arranged trading plan.

Summary

• Peter Altman, who serves as President and CEO and a Director of BioCardia, Inc. (BCDA), purchased 400 shares of the company's common stock.
• The transaction is scheduled for August 12, 2025.
• The shares were acquired at a weighted average price of $1.751 per share, with individual trades ranging from $1.70 to $1.83.
• This purchase was executed under a Rule 10b5-1 pre-arranged trading plan, which allows insiders to set up future trades to avoid accusations of trading on material non-public information.
• Following this transaction, Peter Altman will directly beneficially own 167,962 shares of BioCardia common stock.

Sentiment

Score: 7

Explanation: The insider purchase by the CEO, even if small, generally indicates management confidence. The 10b5-1 plan suggests a pre-planned, non-event-driven transaction, which is neutral to positive, reinforcing a stable outlook.

Positives

• Insider buying by the President and CEO can signal confidence in the company's future prospects and valuation.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary purchase, which adds transparency.

Negatives

• The number of shares purchased (400) is relatively small compared to the total beneficial ownership (167,962 shares), which might limit the perceived strength of the insider signal.

Future Outlook

The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled future purchase, which suggests a long-term perspective from management regarding the company's value.

Industry Context

Insider purchases in the biotechnology sector can be viewed positively, especially for smaller companies like BioCardia, as they may signal management's belief in upcoming clinical milestones or product development success. Such transactions, even if small, can contribute to investor confidence in a sector often characterized by high risk and high reward.

Comparison to Industry Standards

• Insider buying, even in small amounts, is generally seen as a positive signal across industries, indicating management's confidence in the company's prospects.
• While the volume of this specific transaction is modest, it aligns with a pattern of management confidence often observed in growth-oriented biotech firms.
• No specific comparable companies, projects, or results are mentioned in this filing to provide a direct quantitative comparison.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management confidence in the company's future performance and stock value.

Key Dates

Recommendation

The purchase of shares by the CEO, Peter Altman, signals management's confidence in BioCardia's future. However, the relatively small volume of shares acquired (400 shares) limits the strength of this signal. Without additional financial or operational updates, this transaction alone is not sufficient to warrant a strong buy or sell recommendation, suggesting a 'hold' position for existing investors.

Keywords

BioCardia, BCDA, Insider Trading, Form 4, Peter Altman, CEO, Stock Purchase, 10b5-1 Plan, Biotechnology, Healthcare